The active biomolecules in the content assist in the pharmacological effects of beta2-adrenergic receptor agonists by partly helping to bind to intracellular adenylate cyclase (an enzyme that catalyzes the conversion of adenosine triphosphate (ATP) to cyclic adenosine monophosphate (cAMP)). High levels of cAMP cause relaxation of bronchial smooth muscle. The content, which is equivalent to a long-acting beta2-adrenergic agonist effect, has shown that the agonist activity in beta2 receptors is many times greater than that in beta1 receptors and much greater than that in beta3 receptors.
It has a bronchodilator effect locally in the lungs with biomolecules and minerals in its content. The biomolecule assumes a partial agonist role with nanomolar potency at the human beta2-adrenergic receptor level and exerts its effect. The molecule’s effect starts quickly and has a long duration in isolated human bronchi. Despite beta1-adrenergic receptors being dominant in the human heart, beta2-adrenergic receptors make up 15-50% of the total adrenergic receptors in the heart. Although the exact function of beta2-adrenergic receptors in the heart is not known, their presence increases the likelihood of even highly selective beta2-adrenergic agonists having cardiac effects.
Additionally, the formula content is similar to a combination of a long-acting muscarinic receptor antagonist and a long-acting beta2-adrenergic agonist inhalation. Following interaction with usage, all components assist locally in the respiratory tract and create bronchodilator effects through different mechanisms. The formula content can also be expressed as acting as a long-acting muscarinic receptor antagonist (also known as anticholinergic). The formula content, which acts as a muscarinic receptor antagonist, helps to inhibit the binding of acetylcholine to muscarinic acetylcholine receptors in the respiratory smooth muscle competitively, thus showing a bronchodilator activity.
Additionally, the formula content, which acts as a selective, long-acting beta2-adrenergic receptor agonist (beta2-adrenergic agonist), performs similar functions to the pharmacological effects of beta2-adrenergic agonist drugs, at least in part by stimulating intracellular adenylate cyclase, an enzyme that plays a catalytic role in the conversion of adenosine triphosphate (ATP) to cyclic 3′,5′-adenosine monophosphate (cAMP), and can be associated with them. Increased levels of cAMP, with the help of similar agents such as bronchial smooth muscle relaxation and inhibition of the release of sudden excessive sensitivity agents from cells, especially mast cells.
The formula Imforx AX acts as a selective bronchodilator, commonly used in cases of bronchospasm and respiratory distress by stimulating adrenergic receptors, and has the ability to behave like a short-acting beta 2 adrenergic agonist. The biomolecules in the formula content assist in the relaxation of bronchial smooth muscle by converting ATP to cAMP, partly by activating cyclase, thereby helping to alleviate exacerbations and constrictions.
Additionally, it helps prevent and control the release of mediators from mast cells and eosinophils, which play a significant role in asthma pathogenesis. The formula content is also effective in treating diseases such as bronchial asthma and hyperkalemia. It is especially preferred for support during an asthma attack due to its quick onset of action.
Summary: Imforx AX is a formula that helps relax the muscles in the airways, making it easier to breathe. It is commonly used to treat bronchospasm and respiratory distress. This formula works by stimulating adrenergic receptors and behaves like a short-acting beta 2 adrenergic agonist. The biomolecules in the formula help convert ATP to cAMP, which helps to relieve exacerbations and constrictions.
Additionally, it prevents and controls the release of mediators from mast cells and eosinophils, which can cause asthma symptoms. The formula is also effective in treating diseases such as bronchial asthma and hyperkalemia. It is especially useful during an asthma attack because it works quickly to provide relief.
The formula content functions as a chimeric monoclonal IgG1 antibody that specifically targets the epidermal growth factor receptor (EGFR). The EGFR signaling pathways play a crucial role in controlling cell survival, cell cycle progression, angiogenesis, cell migration, and the control of cellular invasion/metastasis.
The formula helps to exhibit a 5 to 10 times higher affinity for binding to EGFR than endogenous ligands, supports blocking the binding of endogenous EGFR ligands, and prevents the receptor from functioning. It also induces the internalization of EGFR, leading to down-regulation. Moreover, it assists in directing cytotoxic immune effector cells to tumor cells expressing EGFR (antibody-dependent cellular cytotoxicity (ADCC)). Additionally, the formula content does not bind to other unrelated receptors.
The protein product of proto-oncogene RAS plays a crucial role in the downstream effects of EGFR’s signaling pathway. In tumors, the activation of RAS by EGFR leads to an increase in proliferation, survival, and production of pro-angiogenic factors controlled by EGFR. RAS is one of the most frequently activated oncogene families in human cancers. Mutations in certain regions of RAS genes (exons 2, 3, and 4) result in the activation of RAS protein independent of EGFR signals.
Additionally, the formula content exhibits a similar interaction to chimeric monoclonal antibodies used in the treatment of non-Hodgkin’s lymphoma and chronic lymphocytic leukemia. The biomolecule binds to the CD20 protein on the surface of lymphoma and leukemia cells, exhibiting an anti-cancer effect.
CD20 protein is an antigenic structure found on the surface of B-type defense cells, and its exact function is thought to be responsible for calcium uptake into cells and the continuity of calcium concentration. In some B-cell lymphoma and leukemia cells, CD20 is much more densely present than in normal cells. Moreover, the CD20 antigen we mentioned is a tumor marker used in the diagnosis and treatment planning of these cancers (biomarker).
Biomolecules that bind to cancer cells help activate immune system cells called natural killer (NK) cells. NK cells destroy cancer cells through antibody-dependent cellular cytotoxicity. Cytokines released from immune system cells and substances released from the destruction of cancer cells lead to an increase in the influx of immune system cells into the environment, increasing vascular permeability and facilitating the passage of molecules and contents into the tumor. Additionally, biomolecules trigger programmed cell death (apoptosis) by causing some changes in cancer cells.
The formula content provides support for phosphorylation of monophosphate (MP) derivative through cellular thymidine kinase in both infected and uninfected cells. It also supports the phosphorylation of molecule-MP to diphosphate (DP) and then to triphosphate (TP) derivatives through cellular thymidylate kinase and nonspecific kinases. Additionally, TP has the ability to act as an inhibitor and substrate of viral reverse transcriptase. Further proviral DNA formation is blocked by the inclusion of formula-TP in the chain and subsequently termination of the chain.
The competition of molecule-TP with HIV reverse transcriptase is tens of times greater than that with cellular DNA polymerase alpha. The resistance characteristics of thymidine analogues (one of the other similar drugs used) have been well determined. This resistance occurs gradually with the accumulation of specific mutations in codons 41, 67, 70, 210, 215, and 219 of HIV reverse transcriptase. Viruses develop phenotypic resistance to thymidine analogue with a combination of mutations in codons 41 and 215 or with the accumulation of at least four of the six mutations
These thymidine analogue mutations alone do not cause high levels of cross-resistance to any other nucleoside, thus allowing the subsequent use of other reverse transcriptase inhibitors used in treatments. The first results in mutations in codons 62, 75, 77, 116, and 151 of HIV reverse transcriptase, while the second typically involves multi-drug resistance mutations with two different patterns, one including the T69S mutation and the other occurring with the same position of a 6-base pair.
Both of these 13 different patterns of multi-nucleoside resistance mutations significantly limit future therapeutic options. Current data show that the frequency and degree of decreased in vitro susceptibility for early HIV disease is significantly less than that for advanced disease. The in vitro susceptibility of other drugs used in the treatment of HIV and the relationship between treatment and clinical response are still under investigation. The in vitro susceptibility test has not been standardized, and therefore, the results may vary according to methodological factors.
The content of the formula supports selective and competitive binding to postsynaptic α1-adrenoceptors, especially to the α1A and α1D receptor subtypes. It helps to relax the smooth muscles of the prostate and urethra, and thus contributes to an increase in maximum urine flow rate. By relaxing the smooth muscles in the prostate and urethra, it relieves obstruction and helps improve urinary symptoms. As a result, it also helps to improve storage symptoms in which bladder instability plays an important role.
These effects on urinary storage and voiding symptoms are persistent during long-term treatment. The need for surgical intervention or catheterization is significantly delayed. α1-adrenoceptor antagonists can reduce blood pressure by reducing peripheral resistance. During research conducted with the content of the formula, no clinically significant decrease in blood pressure was observed.
Summary: The formula contents help bind selectively and competitively to specific α1-adrenoceptor subtypes, including α1A and α1D, located on certain cells. This results in the relaxation of smooth muscles found in the prostate and urethra, allowing for an increased urine flow rate. By relieving obstructions caused by the contraction of these muscles, it can also improve urinary symptoms. Additionally, it can help alleviate storage symptoms caused by bladder instability.
These benefits persist with long-term use and may delay the need for surgical intervention or catheterization. Although α1-adrenoceptor antagonists can reduce blood pressure, no significant decrease in blood pressure was observed during research conducted with the formula’s contents.
In patient tests conducted after the effect of PostCovid LX, it was observed that spleen and lymph node tissue damage seen in values before starting the medication improved (stem cell effect) with the use of smart molecules and the values remained in the desired range. This is evidence that T cells also begin to improve in their response to COVID-19 attacks. It has also been observed that the antibody levels of our users increase significantly and maintain stability over a long period of time.
This shows that individuals who use Post COVID LX can stop the pathogen with the use of the medication, even if they haven’t been infected yet, while those who have recovered from the disease can prevent further infection. Particularly, in the elderly, low antibody and immunity levels were observed in contrast to PostCOVID LX users. It has been revealed that T cells provide great support to antibody cells and are not sufficient alone against the virus.
The effect mechanism of PostCovid LX is to find viruses that show adherence to the body, like special virus or other pathogen hunter T cells, and triggers antibody cells. It enters the cell through the entry route of the virus, and after detection, it prevents the formation of colonies and then destroys the virus with all its power.
The content of the formula shows its supportive effects on the body through two mechanisms. Firstly, it aids in reducing the levels of acetyl-CoA in cells, which activates the glycolytic pathway. Secondly, it supports the passage of long-chain fatty acids through the mitochondrial membrane and plays a role in the β-oxidation of fatty acids. Of course, this effect leads to a decrease in body fat reserves and increases oxygen uptake by opening up the airways and increasing blood oxygen saturation, resulting in weight loss.
The biomolecules in the content are already known to have many benefits and have been recommended for use in many different diseases after numerous studies have been conducted in the past. One of the most important benefits of using biomolecule content is that it increases blood circulation and flow. By turning into nitric oxide and widening blood vessels, it performs this function. There are many advantages to this. Your immune system gets stronger, fertility increases, and your detox ability improves. Another benefit of the formula is that it helps with hormone functioning, especially growth hormone and insulin, which are the most important ones. These hormones provide an increase in physical performance, endurance, and strength.
• Ability to fight inflammation
• Supports reducing the risk of atherosclerosis and vascular disease
• Supports the repair of blood vessels
• Helpful in congestive and coronary heart diseases
• Useful in lowering high blood pressure
• Supportive in increasing athletic performance
• Assists in strengthening the immune system
• Helps alleviate muscle pain
• Supports the regulation of kidney functions
• Helps regulate mental activity
• Assists in fighting dementia
• Helpful in erectile dysfunction and male infertility
• Useful against cold and flu